42 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26670264	73	Fragment-Based Discovery of 2-Aminoquinazolin-4(3H)-ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepsins I, II, and IV.	Latvian Institute of Organic Synthesis
26188621	2	Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.	Guru Ghasidas Vishwavidyalaya (A Central University)
24900843	60	Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit.	Latvian Institute of Organic Synthesis
24631188	12	Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.	Kyoto Pharmaceutical University
24900778	1	Evaluation of aminohydantoins as a novel class of antimalarial agents.	Saint Louis University
23466235	5	Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening.	East China University of Science and Technology
22884991	9	Antiplasmodial activities of 4-aminoquinoline-statine compounds.	Universit£
18417344	6	Identification of acridinyl hydrazides as potent aspartic protease inhibitors.	University of Karachi
15139758	50	Incorporating molecular shape into the alignment-free Grid-Independent Descriptors.	Universitat Pompeu Fabra
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
15125962	9	Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'.	University of Milan
9873534	36	Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.	Pharmacopeia
22204908	22	New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: synthesis and analysis of structure-activity relationships.	University of Karachi
21531557	16	Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.	Trinity College
20466465	1	Quinolines and structurally related heterocycles as antimalarials.	National Institute of Pharmaceutical Education and Research
20634066	13	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution.	Kyoto Pharmaceutical University
20438064	14	Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.	Wayne State University
19635672	35	alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.	Uppsala University
19361896	5	Recent developments in the design and synthesis of hybrid molecules based on aminoquinoline ring and their antiplasmodial evaluation.	Universidad Industrial De Santander
19328682	13	Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases.	National University of Singapore
18952439	34	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.	Kyoto Pharmaceutical University
11975483	10	New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea.	The University of Mississippi
17400453	17	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.	Kyoto Pharmaceutical University
17149873	20	High antiplasmodial activity of novel plasmepsins I and II inhibitors.	University of Milan
17000102	56	Inhibitors of Plasmepsin II-potential antimalarial agents.	Actelion Pharmaceuticals
16162010	78	Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations.	Uppsala University
15974592	68	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II.	LinköPing University
30856324	31	4-Aryl Pyrrolidines as a Novel Class of Orally Efficacious Antimalarial Agents. Part 1: Evaluation of 4-Aryl- N-benzylpyrrolidine-3-carboxamides.	Saint Louis University
10212129	20	Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II.	University of California
9873703	4	Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D.	Pharmacopeia
31913032	86	Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present).	University of Zambia
31062983	83	Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.	Latvian Institute of Organic Synthesis
30529637	76	Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.	Latvian Institute of Organic Synthesis
29636223	84	2-Aminoquinazolin-4(3H)-one based plasmepsin inhibitors with improved hydrophilicity and selectivity.	Latvian Institute of Organic Synthesis
29983285	4	Antiplasmodial activity of hydroxyethylamine analogs: Synthesis, biological activity and structure activity relationship of plasmepsin inhibitors.	University of Delhi
10580501	2	Kainate receptors are involved in synaptic plasticity.	University of Bristol
15658851	42	Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.	Novartis Pharmaceuticals
15689158	21	Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.	Abbott Laboratories
18072720	30	Stereospecific high-affinity TRPV1 antagonists: chiral N-(2-Benzyl-3-pivaloyloxypropyl) 2-[4-(methylsulfonylamino)phenyl]propionamide analogues.	Seoul National University
12639546	30	Identification of a high-affinity phosphopeptide inhibitor of Stat3.	The University of Texas At Houston